Literature DB >> 6771864

Treatment failures secondary to in vivo development of drug resistance by microorganisms.

B Sugarman, E Pesanti.   

Abstract

In two patients development of resistance to antibiotics by initially sensitive infecting organisms was associated with relapse or persistence of active infection. The first patient developed Staphylococcus epidermidis resistant to chloramphenicol during therapy with this agent for an infection that followed a cerebrospinal fluid shunt, and the second patient developed bacteremia due to ampicillin-resistant Salmonella during therapy with ampicillin. Treatment failure resulting from in vivo development of resistance to antimicrobial agents has been described for most of the major classes of antiinfective drugs and for numerous microorganisms. Although in many of these instances reinfection with a resistant organism cannot be excluded, there are many examples of apparent mutation or initial infection with both sensitive and resistant bacterial populations that is followed by selective multiplication of the resistant population or acquisition of resistance by an initially sensitive infecting organism. This phenomenon can be a cause of treatment failure and has appeared in patients in whom, by available tests, drug levels were found adequate. Isolation days after the institution of antimicrobial therapy of what appears to be the same organism as was initially recovered should prompt repeated sensitivity tests, at least to the agents being administered, if the patient's clinical course has not been one of satisfactory improvement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6771864     DOI: 10.1093/clinids/2.2.153

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

Review 1.  Coagulase-negative staphylococci and the epidemiological typing of Staphylococcus epidermidis.

Authors:  J T Parisi
Journal:  Microbiol Rev       Date:  1985-06

2.  Repeat antimicrobial susceptibility testing of identical isolates.

Authors:  R B Thomson; T M File; R A Burgoon
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

3.  Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study).

Authors:  V Jarlier; T Fosse; A Philippon
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

Review 4.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

5.  High-level vancomycin-resistant enterococci causing hospital infections.

Authors:  A H Uttley; R C George; J Naidoo; N Woodford; A P Johnson; C H Collins; D Morrison; A J Gilfillan; L E Fitch; J Heptonstall
Journal:  Epidemiol Infect       Date:  1989-08       Impact factor: 2.451

6.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 7.  Drug resistance in human pathogenic fungi.

Authors:  K Iwata
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

8.  The activity of ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  M Mraović; M Canić-Radojlović
Journal:  Infection       Date:  1986       Impact factor: 3.553

9.  Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline.

Authors:  A M George; S B Levy
Journal:  J Bacteriol       Date:  1983-08       Impact factor: 3.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.